Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 2/2019

01-10-2019 | Subarachnoid Hemorrhage | Review Article

Systematic Review of Intrathecal Nicardipine for the Treatment of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage

Authors: Shaheryar Hafeez, Ramesh Grandhi

Published in: Neurocritical Care | Issue 2/2019

Login to get access

Abstract

Intrathecal nicardipine has been shown to have some efficacy for the treatment of symptomatic cerebral vasospasm in aneurysmal subarachnoid hemorrhage (aSAH). We performed a PRISMA-based systematic review of intrathecal nicardipine for the treatment of cerebral vasospasm in aneurysmal subarachnoid hemorrhage. A total of 825 articles were reviewed. After duplicates were removed and the search criteria was applied, 9 articles remained that were eligible for inclusion and analysis. 377 patients received a total of 6,596 injections of intrathecal nicardipine for aSAH-related cerebral vasospasm. The cumulative ventriculostomy-associated infection risk was 6%. Intrathecal nicardipine injections for aSAH-related cerebral vasospasm appears efficacious and safe. Administration of 4 mg of nicardipine every 12 hours was the most commonly reported dosing regimen. Intrathecal nicardipine decreases mean flow velocities on transcranial Doppler and reduces angiographic and clinical vasospasm. The infection risk appears to be in-line with studies in which rates of EVD-related infections have been reported.
Appendix
Available only for authorised users
Literature
1.
Connolly ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–37.CrossRef
2.
Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010;41(8):e519–36.CrossRef
3.
Velat GJ, Kimball MM, Mocco J, Hoh BL. Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg. 2011;76(5):446–54.CrossRef
4.
Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. Nimodipine treatment in poor-grade aneurysm patients: results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505–17.CrossRef
5.
Fujiwara K, Mikawa S, Ebina T. Continuous intrathecal administration of nicardipine using a portable infusion pump system for management of vasospasm after subarachnoid hemorrhage. No shinkei geka Neurol Surg. 2001;29(1):23–30.
6.
Haley EC Jr, Kassell NF, Torner JC. Participants: a randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage: a report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78(4):537–47.CrossRef
7.
Ko S-B, Choi HA, Helbok R, Kurtz P, Schmidt JM, Badjatia N, et al. Acute effects of intraventricular nicardipine on cerebral hemodynamics: a preliminary finding. Clin Neurol Neurosurg. 2016;144:48–52.CrossRef
8.
Lu N, Jackson D, Luke S, Festic E, Hanel RA, Freeman WD. Intraventricular nicardipine for aneurysmal subarachnoid hemorrhage related vasospasm: assessment of 90 days outcome. Neurocrit Care. 2012;16(3):368–75.CrossRef
9.
Ehtisham A, Taylor S, Bayless L, Samuels OB, Klein MW, Janzen JM. Use of intrathecal nicardipine for aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm. South Med J. 2009;102(2):150–3.CrossRef
10.
Goodson K, Lapointe M, Monroe T, Chalela JA. Intraventricular nicardipine for refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care. 2008;8(2):247–52.CrossRef
11.
Webb A, Kolenda J, Martin K, Wright W, Samuels O. The effect of intraventricular administration of nicardipine on mean cerebral blood flow velocity measured by transcranial Doppler in the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2010;12(2):159–64.CrossRef
12.
Suzuki M, Doi M, Otawara Y, Ogasawara K, Ogawa A. Intrathecal administration of nicardipine hydrochloride to prevent vasospasm in patients with subarachnoid hemorrhage. Neurosurg Rev. 2001;24(4–6):180–4.CrossRef
13.
Shibuya M, Suzuki Y, Enomoto H, Okada T, Ogura K, Sugita K. Effects of prophylactic intrathecal administrations of nicardipine on vasospasm in patients with severe aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1994;131(1–2):19–25.CrossRef
14.
Toyota A, Nishizawa Y. Cerebral vasospasm after subarachnoid hemorrhage, and inhibitory effect of nicardipine investigated by means of transcranial Doppler ultrasonography. No shinkei geka Neurol Surg. 1991;19(12):1143–50.
15.
Yamamoto M, Ohta T, Toda N. Mechanisms of relaxant action of nicardipine, a new Ca ++-antagonist, on isolated dog cerebral and mesenteric arteries. Stroke. 1983;14(2):270–5.CrossRef
16.
Pasqualin A, Vollmer DG, Marron JA, Tsukahara T, Kassell NF, Torner JC. The effect of nicardipine on vasospasm in rabbit basilar artery after subarachnoid hemorrhage. Neurosurgery. 1991;29(2):183–8.CrossRef
17.
Williams TA, Leslie GD, Dobb GJ, Roberts B, van Heerden PV. Decrease in proven ventriculitis by reducing the frequency of cerebrospinal fluid sampling from extraventricular drains. J Neurosurg. 2011;115(5):1040–6.CrossRef
18.
Inoue T, Shimizu H, Fujimura M, Sato K, Endo H, Niizuma K, et al. Risk factors for meningitis after craniotomy in patients with subarachnoid hemorrhage due to anterior circulation aneurysms rupture. Clin Neurol Neurosurg. 2015;139:302–6.CrossRef
19.
Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51(1):170–82.CrossRef
20.
Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. The Lancet. 2017;389(10069):603–11.CrossRef
21.
Edge therapeutics provides update following interim analysis of phase 3 NEWTON 2 study of EG-1962 in aneurysmal subarachnoid hemorrhage. GlobeNewswire. 28 March 2018.
Metadata
Title
Systematic Review of Intrathecal Nicardipine for the Treatment of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Authors
Shaheryar Hafeez
Ramesh Grandhi
Publication date
01-10-2019
Publisher
Springer US
Published in
Neurocritical Care / Issue 2/2019
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-018-0659-9

Other articles of this Issue 2/2019

Neurocritical Care 2/2019 Go to the issue

Letter to the Editor

Objections to Brain Death Determination: Religion and Neuroscience

Original Work

Feasibility and Safety of Transnasal High Flow Air to Reduce Core Body Temperature in Febrile Neurocritical Care Patients: A Pilot Study

Response to Letter To The Editor

Commentary: Feasibility and Safety of Transnasal High Flow Air to Reduce Core Body Temperature

Neuro-Images

Bedside Cranial Ultrasonography in Patients with Hemicraniectomies: A Novel Window into Pathology

Original Article

Cerebellar Hippocampal and Basal Nuclei Transient Edema with Restricted diffusion (CHANTER) Syndrome

Invited Editorial Commentary

Brain Venous Blood Outflow